The Regulations and Regulatory Practices in the US and EU for Amendments During Drug Development
|
|
- Randall York
- 7 years ago
- Views:
Transcription
1 The Regulations and Regulatory Practices in the US and EU for Amendments During Drug Development May 17, 2011 Beijing, China Alberto Grignolo, Ph.D Corporate Vice President, Global Strategy PAREXEL Consulting
2 What Are Amendments? Amendments are changes in a drug development program and its components (e.g. protocols, manufacturing) They are a normal part of drug development and are very difficult to avoid They must be managed well and carefully Managing amendments is a form of risk management Drug Information Association 2
3 Common Reasons for Amendments Routine processes Add clinical investigators to the clinical plan Modify clinical protocol slightly Evolving commercial environment, competition, other drugs on the market, pricing, cost of goods redesign clinical i l trial (e.g. add comparator arm, change dose regimen, change endpoints, etc.) change manufacturing process (e.g. to improve yield) change formulation (e.g. new excipients) Change dosage form (e.g. from tablet to capsule) Drug Safety change safety monitoring plan Drug Information Association 3 Modify or even discontinue the trial
4 Recommended General Approach to Amendments: The Sponsor Side Justify the amendments rigorously on scientific or commercial grounds Develop arguments why amendments are necessary and beneficial Develop communication plan of the amendments to Authorities; identify pros and cons of amendments Communicate amendments to the Authorities; explain that they are necessary but will not invalidate the drug development program Drug Information Association 4
5 Recommended General Approach to Amendments: The Regulator Side Establish a regulatory framework for accepting and reviewing Amendments Establish a process for accepting and reviewing Amendments, and for communicating decisions to Sponsor Require Sponsor to submit detailed, specific documentation on Amendments, including timelines for implementation of Amendments Drug Information Association 5
6 US FDA Regulations on IND Amendments Code of Federal Regulations TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER D--DRUGS FOR HUMAN USE PART INVESTIGATIONAL NEW DRUG APPLICATION Subpart B--Investigational New Drug Application (IND) Sec Protocol amendments. Sec Information amendments Drug Information Association 6
7 Clinical Protocol Amendments Amendment Types: 1. New Protocol 2. Changes in a Protocol 3. New Investigator 4. Content and Format Drug Information Association 7
8 New Protocol Whenever a sponsor intends to conduct a study that is not covered by a protocol already contained in the IND, the sponsor shall submit to FDA a protocol amendment containing the protocol for the study. Such study may begin provided two conditions are met: 1. The sponsor has submitted the protocol to FDA for its review; and 2. The protocol has been approved by the Institutional Review Board (IRB) with responsibility for review and approval of the study The sponsor may comply with these two conditions in either order. Drug Information Association 8
9 Changes in a Protocol A sponsor shall submit a protocol amendment describing: any change in a Phase 1 protocol that significantly affects the safety of subjects or any change in a Phase 2 or 3 protocol that significantly affects the safety of subjects, the scope of the investigation, or the scientific quality of the study. Drug Information Association 9
10 Changes in a Protocol Examples of changes requiring an amendment under this paragraph include: Any increase in drug dosage or duration of exposure of individual subjects to the drug beyond that in the current protocol, Any significant increase in the number of subjects under study Any significant change in the design of a protocol (such as the addition or dropping of a control group) The addition of a new test or procedure that is intended to improve monitoring for, or reduce the risk of, a side effect or adverse event; or the dropping of a test intended to monitor safety Drug Information Association 10
11 Changes in a Protocol A protocol change may be made provided two conditions are met: 1. The sponsor has submitted the change to FDA for its review; and 2. The change has been approved by the IRB with responsibility for review and approval of the study. The sponsor may comply with these two conditions in either order A protocol change intended to eliminate an apparent immediate hazard to subjects may be implemented immediately provided FDA is subsequently notified by protocol amendment and the reviewing IRB is notified Drug Information Association 11
12 New Investigator A sponsor shall submit a protocol amendment when a new investigator is added to carry out a previously submitted protocol Once the investigator is added to the study, the investigational drug may be shipped to the investigator t and the investigator t may begin participating in the study. The sponsor shall notify FDA of the new investigator within 30 days of the investigator being added. Drug Information Association 12
13 Content and Format A protocol amendment is required to be prominently identified as such (i.e., "Protocol Amendment: New Protocol", "Protocol Amendment: Change in Protocol", or "Protocol Amendment: New Investigator"), and to contain the following: In the case of a new protocol, a copy of the new protocol and a brief description of the most clinically significant differences between it and previous protocols. In the case of a change in protocol, a brief description of the change and reference (date and number) to the submission that contained the protocol. In the case of a new investigator, the investigator's name, the qualifications to conduct the investigation, reference to the previously submitted protocol, and all additional information about the investigator's study Drug Information Association 13
14 Content and Format Reference, if necessary, to specific technical information in the IND or in a concurrently submitted information amendment to the IND that the sponsor relies on to support any clinically significant change in the new or amended protocol. If the reference is made to supporting information already in the IND, the sponsor shall identify by name, reference number, volume, and page number the location of the information. If the sponsor desires FDA to comment on the submission, a request for such comment and the specific questions FDA's response should address. Drug Information Association 14
15 When to Submit Protocol Amendments A sponsor shall submit a protocol amendment for a new protocol or a change in protocol before its implementation. Protocol amendments to add a new investigator or to provide additional information about investigators may be grouped and submitted at 30-day intervals. When several submissions of new protocols or protocol changes are anticipated during a short period, the sponsor is encouraged, to the extent feasible, to include these all in a single submission. Drug Information Association 15
16 Information Amendments Requirement for information amendment. A sponsor shall report in an information amendment essential information on the IND that is not within the scope of a protocol amendment, IND safety reports, or annual report. Examples of information requiring i an information amendment include: 1. New toxicology, chemistry, or other technical information; or 2. A report regarding the discontinuance of a clinical investigation. Drug Information Association 16
17 Information Amendments Content and format of an information amendment. An information amendment is required to bear prominent identification of its contents (e.g., "Information Amendment: Chemistry, Manufacturing, and Control", "Information Amendment: Pharmacology-Toxicology", "Information Amendment: Clinical"), and to contain the following: 1. A statement of the nature and purpose of the amendment. 2. An organized submission of the data in a format appropriate for scientific review. 3. If the sponsor desires FDA to comment on an information amendment, a request for such comment. When submitted. Information amendments to the IND should be submitted as necessary but, to the extent feasible, not more than every 30 days. Drug Information Association 17
18 Practical Examples - US Planned Change Increase patient number from 800 to 1200 Add 8 study sites to facilitate additional patient enrollment Change age range in inclusion criteria from years to >13 years of age The sponsor s Medical Monitor has left the company and another physician has been appointed as Medical Monitor. Manufacturing scale-up difficulty: eliminate talc from the formulation and increase the amount of magnesium stearate The first carcinogenicity study report is complete How to Inform FDA Protocol Amendment: Changes in a Protocol Information Amendment: Clinical Protocol Amendment: Changes in a Protocol Information Amendment: Clinical Information Amendment: CMC Information Amendment: Nonclinical Drug Information Association 18
19 Conclusions: IND Amendments The Amendments process has been in place in the US since 1987 and in general it works well What can go wrong? FDA may not agree with the Amendment Sponsor changes the protocol or manufacturing process very frequently, causing FDA to doubt the sponsor s focus Sponsor implements the Amendment, but later FDA responds and objects to the amendment (suggestion: check with FDA about acceptability of amendment) Drug Information Association 19
20 EU Guidance on CTA Amendments INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Communication from the Commission Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (CT-1) (2010/C 82/01) Drug Information Association 20
21 The Complexity of EU 27 Member States A clinical trial may be conducted only in one Member State or in more than one Member State Each Member State where the trial is conducted has jurisdiction over its CTA and has a national Ethics Committee Drug Information Association 21
22 Amendments are Permitted by EU Law After the commencement of the clinical trial, the sponsor may make amendments to the approved protocol. If those amendments are substantial and are likely to have an impact on the safety of the trial subjects or to change the interpretation of the scientific documents in support of the conduct of the trial, or if they are otherwise significant, the sponsor shall notify the competent authorities of the Member State or Member States concerned of the reasons for, and content of, these amendments and shall inform the ethics committee or committees concerned Notification/submission of information ( 1 ) is only obligatory if the amendment is a substantial amendment. Drug Information Association 22
23 The meaning of substantial Amendments to the trial are regarded as substantial where they are likely to have a significant impact on: the safety or physical or mental integrity of the clinical trial participants, or the scientific value of the trial. It is up to the sponsor to assess whether an amendment is to be regarded as substantial. However, care has to be taken to avoid over-reporting. In particular, not every change to the clinical trial application form is by default to be considered as a substantial amendment. Drug Information Association 23
24 The meaning of substantial The sponsor should assess also whether the combination of substantial amendments lead to changes of the clinical trial to an extent that it has to be considered as a completely new clinical trial, which would then be subject to a new authorisation procedure. Drug Information Association 24
25 Amendments that are typically substantial Change of main objective of the clinical trial; Change of primary or secondary endpoint which is likely to have a significant impact on the safety or scientific value of the clinical trial; Use of a new measurement for the primary endpoint; New toxicological or pharmacological data or new interpretation of toxicological or pharmacological data which is likely to impact on the risk/benefit assessment; A change in the definition of the end of the trial, even if the trial has in practice already ended; Addition of a trial arm or placebo group; Drug Information Association 25
26 Amendments that are typically substantial Change of inclusion or exclusion criteria, such as changes to age range, if these changes are likely to have a significant impact on the safety or scientific value of the clinical trial; Reducing the number of monitoring visits; Change of a diagnostic or medical monitoring procedure which is likely to have a significant impact on the safety or scientific value of the clinical trial; Withdrawal of an Independent Data Monitoring Board; Change of IMPs (Investigational Medicinal Products); Change of dosing of IMPs; Change of mode of administration of IMPs; A change of study design which is likely to have a significant impact on primary or major secondary statistical analysis or Drug Information Association 26 the risk/benefit assessment.
27 Amendments that are typically NOT substantial Changes to the identification of the trial (e.g. Change of title, etc.); The addition/deletion of exploratory/tertiary endpoints; A minor increase in the duration of the trial (< 10 % of the overall time of the trial); An increase in duration of > 10 % of the overall time of the trial, provided d that: t the exposure to treatment with the IMP is not extended, the definition of the end of the trial is unchanged, and monitoring arrangements are unchanged; Drug Information Association 27
28 Amendments that are typically NOT substantial A change in the number of clinical trial participants in the member state concerned, if the total number of participants is identical or the increase/decrease is insignificant in view of the absolute number of participants; A change in the documentation used by the research team for recording study data (e.g. Case report form or data collection form); Additional safety monitoring which is not part of an urgent safety measure but is taken on a precautionary basis; Minor clarifications to the protocol; Correction of typographical errors. Drug Information Association 28
29 Other substantial amendments New toxicological or pharmacological data or new interpretation of toxicological or pharmacological data of relevance for the investigator; Changes to the reference safety information for the annual safety report. A change of sponsor or the sponsor s legal representative; The revocation or suspension of the IMP s marketing authorisation. Drug Information Association 29
30 Other nonsubstantial amendments Any change of persons other than the sponsor or his legal Representative, for example applicant, clinical research associates (CRAs) who monitor the clinical trial for the investigator, and clinical research organisations (CROs) (note that the responsibility vis-à-vis the national competent authority for the clinical trial is always with the sponsor or his legal representative); Any change in the contact details of persons referred to in the documentation ti (see, however, section 3.2 as regards contact t details of the contact person); Changes to the internal organisation of the sponsor or of the persons to whom certain tasks have been delegated; Changes in the logistical arrangements for storing/ transporting samples; Change of technical equipment; Addition or deletion per se of another member state or third country concerned. Drug Information Association 30
31 Who in EU should be notified about substantial amendments? The Member State(s) where the trial is conducted and/or The Ethics Committee(s) with jurisdiction over the trial It is essential that the Member State(s) and the Ethics Committee(s) communicate with each other The EU Commission Guidance 2010/C 82/01 specifies the content and format of communicating substantial amendments Drug Information Association 31
32 How to manage nonsubstantial amendments in EU Sponsor must Document all nonsubstantial amendments and keep them on file Update the Clinical Trial Application Form when submitting a substantial amendment Update the Form with the nonsubstantial amendments when updating the Form with a substantial amendment Drug Information Association 32
33 Time for response and implementation The Ethics Committee(s) and/or the Member State(s) must respond to the applicant within 35 days either approving or not approving the substantial amendment Up until then, the trial can continue on the basis of the original documentation Upon approval, it is the sponsor s responsibility to ensure communication of the changes to the investigators. Drug Information Association 33
34 EU Member States View Amendments Differently: Some Examples Type of Amendment Treated as Substantial Treated as Notification Approval required Increase N of patients total trial Belgium, Czech, Denmark, Finland, France, Romania, Slovakia Poland Estonia, Latvia, Lithuania Enrollment halt Austria, Belgium, Czech, Estonia, Latvia Finland, France, Lithuania, Poland, Germany, NL, Slovakia Romania, UK Sponsor name change Belgium, NL, UK Check, Denmark, Estonia, Finland, France, Germany, Estonia, Lithuania, Poland, Slovakia, Sweden Romania Drug Information Association 34
35 Urgent safety measures Urgent safety measures (e.g. to protect the safety of trial subjects) may be taken without prior notification to the national competent authority. However, the sponsor must inform the national competent authority and the Ethics Committee of the Member State concerned of the new events, the measures taken and the plan for further action as soon as possible. Where the initial contact is by telephone, this should be followed up, for reasons of traceability, by fax or . It should be followed by a written report. Drug Information Association 35
36 Final Thoughts Recommendation to Sponsors: align regulatory and commercial strategies from the start in detail, to try and minimize the need for Amendments that are driven by commercial considerations Recommendation to Regulators: the regulatory framework must allow flexibility and acceptance of amendments without necessarily stopping the trial, because drug development is fluid and sometimes needs to be adjusted The common goal is to promote innovation, rapid development and affordability of innovation for all patients who need therapeutic products Drug Information Association 36
37 Personal Views on Sponsor-Regulator Relationship During Drug Development A Drug Development Plan should be agreed by Sponsor and Regulator up-front, including CMC, nonclinical and clinical aspects The goal: make no changes to the plan But events happen during development, and changes (Amendments) to the Drug Development Plan often become necessary. This is life. Justify any Plan changes very rigorously first internally within the Sponsor, then to the Authorities Establish a framework for clear, detailed and transparent communication between sponsor and regulator regarding amendments based on regulations but also on earned trust Drug Information Association 37
38 Thank You Alberto Grignolo, Ph.D Corporate Vice President, Global Strategy PAREXEL Consulting
Extemporaneously Prepared Early Phase Clinical Trial Materials
Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS, RAC Eli Lilly & Co. Regulatory Advisor International Consortium for Innovation & Quality in Pharmaceutical Development
More informationEUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/F2/BL D(2003) CT 1 Revision 2
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, ENTR/F2/BL D(2003)
More informationHealth Products and Food Branch. www.hc-sc.gc.ca
Health Products and Food Branch 1 HEALTH CANADA PART C DIVISION 5 - DRUGS FOR CLINICAL TRIALS INVOLVING HUMAN SUBJECTS Part C - Division 5 2 Part A: Part B: Part C: Part D: Part E: Part G: Part J: Administration
More informationRoles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
More informationPrincipal Investigator and Sub Investigator Responsibilities
Principal Investigator and Sub Investigator Responsibilities I. Purpose To define the roles and responsibilities of Principal Investigators conducting research at GRU. II. Definition The term Principal
More informationThe Importance of Following the PROTOCOL in Clinical Trials
The Importance of Following the PROTOCOL in Clinical Trials Presentation Objectives: Upon completion of this presentation, participants will be able to: Describe the following terms: Protocol, Protocol
More informationChallenges in the Regulation of Pediatric Clinical Trials
Challenges in the Regulation of Pediatric Clinical Trials Wilson W. Bryan, M.D. FDA / CBER / OCTGT wilson.bryan@fda.hhs.gov National Institutes of Health Recombinant DNA Advisory Committee (RAC) Meeting
More informationEuropean Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Methodology Note for Shire
European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Methodology Note for Shire Contents 1. Overview of the EFPIA Requirements... 3 2.
More informationDate : Date of start of procedure: Authorisation/ positive opinion :
Substantial Amendment Notification Form (Cf. Section 3.7.b of the Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use,
More informationEUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/CT 1. Revision 1
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, ENTR/CT 1 Revision
More informationMutual recognition between the EU member states: official framework for collaboration saves resources?
Mutual recognition between the EU member states: official framework for collaboration saves resources? Alar Irs, Estonia Pre-ICDRA meeting, Nov 28-29, 2010 Effective collaboration: the future for medicines
More informationHistory and Principles of Good Clinical Practice
History and Principles of Good Clinical Practice Cristina E. Torres, Ph.D. Social Science Professor, UPM-NIH FERCAP Coordinator ICH: International Conference on Harmonization GCP: Good Clinical Practices
More informationQuality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials. Agenda Topics for Discussion
Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS Eli Lilly & Co. Principal Consultant - Regulatory PDA/FDA Joint September 20 th, 2011
More informationThe EU Clinical Trial Regulation A regulator s perspective
5 The EU Clinical Trial A regulator s perspective Author Martyn Ward, Group Manager, Licensing, Medicines and Healthcare products Regulatory Agency (MHRA), UK. Keywords Clinical Trial Directive (the Directive);
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON DATA MONITORING COMMITTEES
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 27 July 2005 Doc. Ref. EMEA/CHMP/EWP/5872/03 Corr COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
More informationClinical trials regulation
Clinical trials regulation The Proposal for a Regulation of the European Parliament and of the Council on Clinical Trials on Medicinal Products for Human Use and Repealing Directive 2001/20/EC an update
More informationFebruary 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
More informationINTERNATIONAL TRACKED POSTAGE SERVICE
INTERNATIONAL TRACKED POSTAGE SERVICE Index Expanding Internationally...03 The Post NL Service...04 How it works... 05 Post NL Rates...06 Transit times...07 Customer Service...08 Expanding Internationally
More informationUK Implementation of the EU Clinical Trial Directive 2001/20/EC:
UK Implementation of the EU Clinical Trial Directive 2001/20/EC: GCP Aspects. Dr. Colin Wilsher, FRQA. BARQA GCP Committee Chairman; & Pfizer Worldwide Development Quality Assurance. GIQAR, Roma, October
More informationST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
More informationClinical Study Startup Timelines in Central and Eastern Europe
Vol. 11, No. 10, October 2015 Happy Trials to You Clinical Study Startup Timelines in Central and Eastern Europe By Vlad Bogin The complexity of regulatory approval pathways and time to first-site initiation
More informationManual for Submission of Changes, Amendments, Suspensions, and Cancellations v.1
[Brazilian Health Surveillance Agency] Manual for Submission of Changes, Amendments, Suspensions, and Cancellations v.1 Brasília, 2015 Copyright 2015: Brazilian Health Surveillance Agency. The partial
More informationCONDUCTING GLOBAL CLINICAL RESEARCH TRIALS:
CONDUCTING GLOBAL CLINICAL RESEARCH TRIALS: COMPARING AND CONTRASTING FDA MEDICAL DEVICE REGULATIONS FOR CLINICAL INVESTIGATORS WITH ISO 14155:2011 Introduction Today s clinical research landscape for
More information- Assessment of the application by Member States of European Union VAT provisions with particular relevance to the Mini One Stop Shop (MOSS) -
- Assessment of the application by Member States of European Union VAT provisions with particular relevance to the Mini One Stop Shop (MOSS) - BACKGROUND The information available on this website relates
More informationThe New EU Clinical Trials Regulation: The Good, the Bad, the Ugly
A Full-Service International CRO The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly Dr. Martine Dehlinger-Kremer Vice President, Global Medical and Regulatory Affairs The original intent
More informationSubject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
More informationStandard Operating Procedure. Clinical Trial Authorisation
Standard Operating Procedure for Clinical Trial Authorization Scope This SOP has been written to describe the procedure undertaken to apply for Clinical Trial Authorisation from Competent Authorities in
More informationThe Clinical Trials Regulation EU No 536/2014: and Phase I trials
The Clinical Trials Regulation EU No 536/2014: and Phase I trials EUFEMED, Brussels, 20 May 2015 Presented by Fergus Sweeney Head, Inspections and Human Medicines Pharmacovigilance An agency of the European
More informationEarly Phase Clinical Trials: Public Access to the EU Database Repository
European CRO Federation Via Lucrezio Caro, 63 00193 Roma, Italy Tel.: +39 06 807 60 72 Fax: +39 06 807 60 85 Email: info@eucrof.eu Internet: www.eucrof.eu Early Phase Clinical Trials: Public Access to
More informationPRIMING GRANT FUNDING GUIDELINES
PRIMING GRANT FUNDING GUIDELINES Definitions European Union (EU) Member State Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland,
More informationEU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
More informationSURVEY ON THE TRAINING OF GENERAL CARE NURSES IN THE EUROPEAN UNION. The current minimum training requirements for general care nurses
SURVEY ON THE TRAINING OF GENERAL CARE NURSES IN THE EUROPEAN UNION This survey serves as a background document for the discussion of the Commission's legislative proposal to modernize the minimum requirements
More informationEMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART
EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,
More informationCULTURAL AND CREATIVE SECTORS GUARANTEE FACILITY
CULTURAL AND CREATIVE SECTORS GUARANTEE FACILITY OPEN CALL FOR EXPRESSION OF INTEREST TO SELECT FINANCIAL INTERMEDIARIES UNDER THE CULTURAL AND CREATIVE SECTORS GUARANTEE FACILITY (Published on 18th July
More informationERASMUS+ MASTER LOANS
ERASMUS+ MASTER LOANS Erasmus+ Master Loan: opening up access to more affordable lending for cross-border studies The Erasmus+ programme makes it possible for students who want to take a full Masters level
More informationGuidance for Industry
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs & As DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationClinical research: where are we with the new (Paediatric) RC trial Regulation
where are we with the new (Paediatric) RC trial Regulation, MD, PhD Ethical Committee DEEP Former member of the PDCO EMA With the aid of Fabio D'Atri European commission and Anabela Marcal of EMA The new
More informationNEW PASSENGER CAR REGISTRATIONS BY ALTERNATIVE FUEL TYPE IN THE EUROPEAN UNION 1 Quarter 4 2015
NEW PASSENGER CAR REGISTRATIONS BY ALTERNATIVE FUEL TYPE IN THE Quarter 4 2015 Alternative fuel vehicle (AFV) registrations: +20.0% in 2015; +21.1% in Q4 In the fourth quarter of 2015, total alternative
More informationThe New EU Clinical Trial Regulation Potential Impacts on Sites
The New EU Clinical Trial Regulation Potential Impacts on Sites Angela Papa Associate Director, Clinical Management PPD Pierre-Frédéric Omnes Director, Site Start-Up and Regulatory INC Research Faculty
More informationPediatric Research Networks A Plan for a Collaboration in Europe. Daniela Gunz Head Clinical Trial Operations Switzerland June 9, 2011
Pediatric Research Networks A Plan for a Collaboration in Europe Daniela Gunz Head Clinical Trial Operations Switzerland June 9, 2011 Agenda Challenges in clinical research in children EU pediatric regulation
More informationStandard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager
Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s Author: Lisa Austin, Research Manager Purpose and Objective: To identify and standardise
More informationThe Guardianship Service
The Guardianship Service How can they help you? When you arrive in Belgium Are you under the age of 18 and have you arrived in Belgium without your father or mother? You are searching for support and accommodation
More informationQualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015
Qualified Persons in the Pharmaceutical Industry Code of Practice 2009, updated August 2015 *QP Code of Practice 2008 updated Aug15 Page 1 of 13 Code of Practice for Qualified Persons 1. INTRODUCTION 2.
More informationand Regulatory Aspects
Good Clinical Practice and Regulatory Aspects Nora Espiritu MD, MPh, PhD (c) Former Executive Director of Research and Technology Transfer. Peruvian National Institute t of Health. Member of the Ethics
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol
More informationGuidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
More informationSheffield Kidney Institute. Planning a Clinical Trial
Planning a Clinical Trial Clinical Trials Testing a new drug Ethical Issues Liability and Indemnity Trial Design Trial Protocol Statistical analysis Clinical Trials Phase I: Phase II: Phase III: Phase
More informationIndustry Experience in Clinical Trials Management. Catherine Lee Area Head Clinical Operations Asia Pfizer Inc 20 May 2011 Brussels
Industry Experience in Clinical Trials Management Catherine Lee Area Head Clinical Operations Asia Pfizer Inc 20 May 2011 Brussels Stakeholders in clinical research Critical activities to ensure patient
More informationJob Profile Clinical Research Associate III (CRA)
PART 1 - PROFILE You are an experienced CRA with a strong background in Clinical Research who is passionate about drug development and are seeking a challenging and rewarding career in a quality focussed
More informationGOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE
ICH E6 GCP: Consolidated Guideline: Investigator 1/7 Institutional Review Board Services ICH HARMONIZED TRIPARTITE GUIDELINE E6: GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE 4. INVESTIGATOR 4.1 Investigator's
More informationOverview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
More informationGuidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects
Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More informationThis factsheet contains help and information for financial advisers who wish to advise their clients who live in Europe.
Financial Conduct Authority Factsheet No.025 Investment advisers Passporting This factsheet contains help and information for financial advisers who wish to advise their clients who live in Europe. Introduction
More informationCLINICAL RESEARCH PROTOCOL CHECKLIST
CLINICAL RESEARCH PROTOCOL CHECKLIST [taken from ICH GCP : Guidance for Industry, Good Clinical Practice: Consolidated Guidance, Revision 1 (R1) June 1996] ICH GCP, Section 6. CLINICAL TRIAL PROTOCOL AND
More informationRECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING
RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING July 2006 TABLE OF CONTENTS Page 1. Introduction 2 2. Scope 2 3. Documents to be archived 2 4. Quality of essential documents 10 5.
More informationEU Clinical Trials Regulation Regulation EU 536/2014
EU Clinical Trials Regulation Regulation EU 536/2014 María Jesús Zafra Director, QA & Compliance Table of contents 1 2 3 4 Introduction Timelines and main changes Highlights 5 Impact on company processes
More informationOECD Recommendation on the Governance of Clinical Trials
OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside
More informationGuide to Clinical Trial Applications
Guide to Clinical Trial Applications AUT-G0001-9 DATE 29 JUNE 2015 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities
This Guidance Document is to ensure that investigators and research personnel recognize their responsibilities associated with the conduct of human subject research by outlining their responsibilities,
More informationOrientation Manual for Clinical Research Coordinators
Orientation Manual for Clinical Research Coordinators Maine Medical Center Research Institute Page 1 of 19 Version 1 (2009) MAINE MEDICAL CENTER RESEARCH INSTITUTE Statement of Mission, Vision, Goals and
More informationSUBMISSION BY DENMARK AND THE EUROPEAN COMMISSION ON BEHALF OF THE EUROPEAN UNION AND ITS MEMBER STATES
SUBMISSION BY DENMARK AND THE EUROPEAN COMMISSION ON BEHALF OF THE EUROPEAN UNION AND ITS MEMBER STATES Copenhagen, 19 April 2012 Subject: Information on the quantified objectives (QELROs) for the second
More informationERASMUS+ MASTER LOANS
Ref. Ares(2015)660570-17/02/2015 ERASMUS+ MASTER LOANS Erasmus+ Master Loan: opening up access to more affordable lending for cross-border studies The Erasmus+ programme makes it possible for students
More informationStudents: undergraduate and graduate students who are currently enrolled in universities
DUO-Korea: 1. General Description CAUTION: If any application falls under the following 3 cases, the application is disqualified and will not be considered for selection. If such case is found after the
More informationClinical Trial Protocol Development. Developed by Center for Cancer Research, National Cancer Institute Endorsed by the CTN SIG Leadership Group
Clinical Trial Protocol Development Developed by Center for Cancer Research, National Cancer Institute Endorsed by the CTN SIG Leadership Group Objectives The clinical trial protocol is the heart of any
More informationOperational aspects of a clinical trial
Operational aspects of a clinical trial Carlo Tomino Pharm.D. Coordinator Pre-authorization Department Head of Research and Clinical Trial Italian Medicines Agency Mwanza (Tanzania), June 11, 2012 1 Declaration
More informationHarmonizing Change Control Processes Globally
Quality & Compliance Associates, LLC Harmonizing Change Control Processes Globally President Quality & Compliance Associates, LLC When We Deal In A Global Environment, How Do We Design A System That Addresses
More informationDavid M. Stern, M.D. JAN 2 9 7007 Dean, University of Cincinnati College of Medicine 231 Albert Sabin Way Cincinnati, OH 45267
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Serv ice Food and Drug Administration 9200 Corporate Boulevard Rockville, Ma ry land 20850 WARNING LETTER VIA FEDERAL EXPRESS David M. Stern, M.D. JAN
More informationDecember 13, 2011 Maureen Coyne
December 13, 2011 Maureen Coyne No industry relationships No financial conflicts of interests Recent experience weighted toward industrysponsored clinical trials Information based on my experiences IRB
More informationSerious Breaches. Ian Gravenor. Senior Clinical Project Manager Novo Nordisk Ltd
Serious Breaches Ian Gravenor Senior Clinical Project Manager Novo Nordisk Ltd Serious Breaches of GCP or the Trial Protocol Agenda Why report? The legislation MHRA Guidance document Timelines Actions
More information72/2015-21 April 2015
72/2015-21 April 2015 Provision of deficit and debt data for 2014 - first notification Euro area and EU28 government deficit at 2.4% and 2.9% of GDP respectively Government debt at 91.9% and 86.8% In 2014,
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration
More informationHealth Canada s GCP Compliance Program. GCP Information Sessions November 2010
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program GCP Information Sessions November 2010 Objective To describe the role that Health
More informationKeeping European Consumers safe Rapid Alert System for dangerous non-food products 2014
Keeping European Consumers safe Rapid Alert System for dangerous non-food products 2014 COMPLETE STATISTICS Justice and Consumers Directorate-General for Justice and Consumers Directorate Consumers Unit
More informationGuidance on IRB Continuing Review of Research
NOTE: THIS GUIDANCE SUPERSEDES OHRP S JANUARY 15, 2007 GUIDANCE ENTITILED GUIDANCE ON CONTINUING REVIEW. CLICK HERE FOR THE JANUARY 15, 2007 GUIDANCE. Office for Human Research Protections Department of
More informationThe Australian Clinical Trial Handbook
The Australian Clinical Trial Handbook A simple, practical guide to the conduct of clinical trials to International standards of Good Clinical Practice (GCP) in the Australian context About the Therapeutic
More informationREPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL
EUROPEAN COMMISSION Brussels, 25.9.2014 COM(2014) 592 final REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL on the implementation in the period from 4 December 2011 until 31 December
More information1.2 - Overview of Regulation of Clinical Trials in Canada
1.2 - Overview of Regulation of Clinical Trials in Canada Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationErasmus Mundus Master in Membrane Engineering EM 3 E Third Call for Applications
Erasmus Mundus Master in Membrane Engineering EM 3 E Third Call for Applications Master edition 2013-2015 Erasmus Mundus is a cooperation and mobility programme in the field of higher education, promoted
More informationInvestigational Drugs: Investigational Drugs and Biologics
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place
More informationRegulatory Expectations for GMP: What s Happening. Patricia Weideman, PhD Director, Product Quality & Occupational Toxicology Genentech, Inc.
Regulatory Expectations for GMP: What s Happening Patricia Weideman, PhD Director, Product Quality & Occupational Toxicology Genentech, Inc. Topics Background for changes and expectations of regulatory
More informationHow To Fund A Project
PREPARATORY ACTION IN THE FIELD OF SPORT Administrative and Financial Management Handbook The rules outlined in this Administrative and Financial Handbook apply to the projects funded by the Preparatory
More informationGlossary of Clinical Trial Terms
Glossary of Clinical Trial Terms ADVERSE REACTION: (Adverse Event): Also known as side effects, adverse reactions include any undesired actions or effects of the experimental drug or treatment. Experimental
More informationThe European Clinical Trials Framework Update on the Draft Clinical Trials Regulation
The European Clinical Trials Framework Update on the Draft Clinical Trials Regulation Dr. Ilona Reischl BASG/AGES Austrian Agency for Health and Food Safety GmbH Content - References "Proposal for a Regulation
More informationEUF STATISTICS. 31 December 2013
. ESTIMATES OF EU TURNOVER VOLUMES. Turnover volumes by product, allocation and notification (Estimates of EU s, Millions of ) Estimate of the EU % on Turnover Significance of the sample on total turnover
More informationEUROPE 2020 TARGETS: RESEARCH AND DEVELOPMENT
EUROPE 2020 TARGETS: RESEARCH AND DEVELOPMENT Research, development and innovation are key policy components of the EU strategy for economic growth: Europe 2020. By fostering market take-up of new, innovative
More informationInformation for applicants, employers and supervisors. Periods of adaptation
Information for applicants, employers and supervisors Periods of adaptation Contents Introduction 1 Section one: Information for applicants, employers and supervisors 4 Section two: Guidance for applicants
More informationTPI: Traffic Psychology International on a common European curriculum for postgraduate education in traffic psychology
TPI: Traffic Psychology International on a common European curriculum for postgraduate education in traffic psychology Sucha, M.*, Sramkova, L.** DeVol, D.* * TPI - Traffic Psychology International **
More informationSUPPLEMENTARY PROTECTION CERTIFICATES FOR MEDICINAL PRODUCTS
SUPPLEMENTARY PROTECTION CERTIFICATES FOR MEDICINAL PRODUCTS A Supplementary Protection Certificate (SPC) is an Intellectual Property right which can give up to five extra years of exclusivity after a
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Russia
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Russia Question 1: What laws or regulations apply to an application for conducting a clinical
More informationGuidance for Industry
Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center
More informationRegulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
More informationCLINICAL RESEARCH ROLES CLINICAL RESEARCH ROLESCLINICAL RESEARCH ROLES
CLINICAL RESEARCH ROLESCLINICAL RESEARCH ROLES 1. Clinical Study Team Principal Investigator Co Principal Investigator (Co PI) Research Coordinator Study Monitor Data manage Sponsor Post Doctoral Scholar
More informationEBA REPORT ON THE BENCHMARKING OF DIVERSITY PRACTICES. EBA-Op-2016-10 08 July 2016
EBA REPORT ON THE BENCHMARKING OF DIVERSITY PRACTICES EBA-Op-2016-10 08 July 2016 BENCHMARKING OF DIVERSITY PRACTICES AT THE EU LEVEL Benchmarking of diversity practices at the European Union level List
More informationAccess to social housing supports for non-irish nationals including clarification re Stamp 4 holders
Housing Circular 41/2012 December, 2012 To: Directors of Service (Housing) Town Clerks Access to social housing supports for non-irish nationals including clarification re Stamp 4 holders Dear Director/Town
More informationThe European regulatory system for medicines and the European Medicines Agency
The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended
More informationTemplate for essential information to be provided for proposals including clinical trials / studies / investigations
Template for essential information to be provided for proposals including clinical trials / studies / investigations Document history Version 2016callsV1 September 2015 Modifications (compared to previous
More informationEquity Release Schemes in the European Union
Reifner Clerc-Renaud Perez-Carillo Tiffe Knobloch Equity Release Schemes in the European Union institut fur finanzdienstleistungen e.v. Contents PREFACE I EXECUTIVE SUMMARY V TABLES XXIX FIGURES XXX 1.
More information12.0 Investigator Responsibilities
v. 5.13.13 12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement,
More informationReport and Commentary on the Eurodoc Statement of Standards in the Assessment, Expectations and Outcomes of Doctoral Programmes in Europe
Report and Commentary on the Eurodoc Statement of Standards in the Assessment, Expectations and Outcomes of Doctoral Programmes in Europe Edited by Tim Brown Supervision and Training Workgroup Coordinator
More informationInsurance and compensation in the event of injury in Phase I clinical trials
Insurance and compensation in the event of injury in Phase I clinical trials Guidance developed by the Association for the British Pharmaceutical Industry, the BioIndustry Association and the Clinical
More information